Pfizer Inc.
ANTIBODIES TO COAGULATION FACTOR XIA AND USES THEREOF
Last updated:
Abstract:
In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
Status:
Application
Type:
Utility
Filling date:
23 Jun 2021
Issue date:
30 Dec 2021